Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 1, 2012, Pages 99-111

  Cheung, Yin Ting ^a   Chui, Wai Keung ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Breast cancer; Chemotherapy; Cognitive function; Neurological; Neuropsychological; Psycho oncology

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA; VINBLASTINE;

ADULT; AGED; ANEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84984555355     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.09.001     Document Type: Review

References (80)

1. Ruzich M., Ryan B., Owen C., Delahunty A., Stuart-Harris R. Prospective evaluation of cognitive function in patients with early breast cancer receiving adjuvant chemotherapy. Asia Pac J Clin Oncol 2007, 3:125-133.
2. Quesnel C., Savard J., Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009, 116:113-123.
3. Schagen S.B., Muller M.J., Boogerd W., Mellenbergh G.J., van Dam F.S.A.M. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006, 98:1742-1745.
4. Collins B., Mackenzie J., Stewart A., Bielajew C., Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 2009, 18:134-143.
5. Mehlsen M., Pedersen A.D., Jensen A.B., Zachariae R. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 2009, 18:248-257.
6. Jansen C.E., Cooper B.A., Dodd M.J., Miaskowski C.A. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 2010, 1-10.
7. Wefel J.S., Saleeba A.K., Buzdar A.U., Meyers C.A. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010, 116:3348-3356.
8. Ahles T.A., Saykin A.J., McDonald B.C., Furstenburg C.T., Yuelin L., Hanscom B.S., et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010, 28:4434-4440.
9. Stewart A., Collins B., Mackenzie J., Tomiak E., Verma S., Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 2008, 17:122-130.
10. Debess J., Riis Jã, Engebjerg M.C., Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 2010, 121:91-100.
11. Bender C.M., Sereika S.M., Berga S.L., Vogel V.G., Brufsky A.M., Paraska K.K., et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006, 15:422-430.
12. Jim H.S.L., Donovan K.A., Small B.J., Andrykowski M.A., Munster P.N., Jacobsen P.B. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 2009, 115:1776-1783.
13. Jansen C.E., Dodd M.J., Miaskowski C.A., Dowling G.A., Kramer J. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology 2008, 17:1189-1195.
14. Wefel J.S., Lenzi R., Theriault R.L., Davis R.N., Meyers C.A. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004, 100:2292-2299.
15. Hermelink K., Untch M., Lux M.P., Kreienberg R., Beck T., Bauerfeind I., et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007, 109:1905-1913.
16. Tager F.A., McKinley P.S., Schnabel F.R., El-Tamer M., Cheung Y.K.K., Fang Y., et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 2010, 123:25-34.
17. Jenkins V., Shilling V., Deutsch G., Bloomfield D., Morris R., Allan S., et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006, 94:828-834.
18. Brain E.G.C., Mertens C., Girre V., Rousseau F., Blot E., Abadie S., et al. Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: a French Geriatric Oncology Group (GERICO) phase II multicentre trial. Crit Rev Oncol Hematol 2010, 10.1016/j.critrevonc.2010.10.0030.
19. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485-493.
20. Boykoff N., Moieni M., Subramanian S.K. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 2009, 3:1-10.
21. Castellon S., Ganz P.A. Neuropsychological studies in breast cancer: in search of chemobrain. Breast Cancer Res Treat 2009, 116:125-127.
22. Hurria A., Goldfarb S., Rosen C., Holland J., Zuckerman E., Lachs M.S., et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat 2006, 98:343-348.
23. Hurria A., Somlo G., Ahles T. Renaming chemobrain. Cancer Invest 2007, 25:373-377.
24. Rugo H.S., Ahles T. The Impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol 2003, 30:749-762.
25. Schagen S.B., Muller M.J., Boogerd W., Van Dam F.S. Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective. Clin Breast Cancer 2002, 3(Suppl 3):S100-S108.
26. Schagen S.B., Vardy J. Cognitive dysfunction in people with cancer. Lancet Oncol 2007, 8:852-853.
27. Scherwath A., Mehnert A., Schleimer B., Schirmer L., Fehlauer F., Kreienberg R., et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006, 17:415-423.
28. Tchen N., Juffs H.G., Downie F.P., Yi Q.L., Hu H., Chemerynsky I., et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003, 21:4175-4183.
29. Van Dam F.S.A.M., Schagen S.B., Muller M.J., Boogerd W.V.D., Wall E., Droogleever Fortuyn M.E, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998, 90:210-218.
30. Vardy J. Cognitive function in breast cancer survivors. Cancer Treat Res 2009, 151:387-419.
31. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7:192-201.
32. Anderson-Hanley C., Sherman M.L., Riggs R., Agocha V.B., Compas B.E. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003, 9:967-982.
33. Morse R., Rodgers J., Verrill M., Kendell K. Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review. Eur J Cancer 2003, 39:2288-2297.
34. Mehnert A., Scherwath A., Schirmer L., Schleimer B., Petersen C., Schulz-Kindermann F., et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007, 66:108-118.
35. Reid-Arndt S.A., Hsieh C., Perry M.C. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology 2010, 19:535-544.
36. Mehnert A. Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol 2011, 77:109-130.
37. Cunningham R.S. Anemia in the oncology patient: cognitive function and cancer. Cancer Nurs 2003, 26:38S-42S.
38. Jacobsen P.B., Garland L.L., Booth-Jones M., Donovan K.A., Thors C.L., Winters E., et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004, 28:7-18.
39. Schagen S.B., Das E., van Dam F.S.A.M. The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psychooncology 2009, 18:674-678.
40. Servaes P., Verhagen CAHHVM, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. Cancer 2002, 95:2017-2026.
41. Vearncombe K.J., Rolfe M., Wright M., Pachana N.A., Andrew B., Beadle G. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 2009, 15:951-962.
42. Dietrich J., Han R., Yang Y., Mayer-Pröschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5. Article 22.
43. Meyers C.A. How chemotherapy damages the central nervous system. J Biol 2008, 7. Article 11.
44. Vardy J. Neurocognitive effects of chemotherapy in adults. Australian Prescriber 2008, 31:22-24.
45. Vardy J., Rourke S., Tannock I.F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007, 25:2455-2463.
46. Matsuda T., Takayama T., Tashiro M., Nakamura Y., Ohashi Y., Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 2005, 12:279-287.
47. Jacobs S.R., Jacobsen P.B., Booth-Jones M., Wagner L.I., Anasetti C. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoetic stem cell transplant patients. J Pain Symptom Manage 2007, 33:13-23.
48. Wefel J.S., Vardy J., Ahles T., Schagen S.B. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011, 12:703-708.
49. Winocur G., Vardy J., Binns M.A., Kerr L., Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006, 85:66-75.
50. Seigers R., Schagen S.B., Beerling W., Boogerd W., van Tellingen O., van Dam F.S.A.M., et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008, 186:168-175.
51. Cardoso S., Santos R.X., Carvalho C., Correia S., Pereira G.C., Pereira S.S., et al. Doxorubicin increases the susceptibility of brain mitochondria to Ca2+-induced permeability transition and oxidative damage. Free Radic Biol Med 2008, 45:1395-1402.
52. Granados-Principal S., Quiles J.L., Ramirez-Tortosa C.L., Sanchez-Rovira P., Ramirez-Tortosa M. New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem Toxicol 2010, 48:1425-1438.
53. Han R., Yang Y.M., Dietrich J., Luebke A., Mayer-Pröschel M., Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008, 7.
54. Fisher B., Brown A.M., Dimitrov N.V., Poisson R., Redmond C., Margolese R.G., et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990, 8:1483-1496.
55. National Cancer Institute. 2010. Comparative analyses: modeling future mortality benefits associated with recent treatment advances. [accessed on 05.08.11]. http://cisnet.cancer.gov/breast/comparative.html.
56. Carlson R.W., Brown E., Burstein H.J., Gradishar W.J., Hudis C.A., Loprinzi C., et al. NCCN Task Force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006, 4:S-1-S-26.
57. D'Orazio A.I. Improvement in disease-free survival with doxorubicin/docetaxel/cyclophosphamide (TAC) versus 5-fluorouracil/doxorubicin/cyclophosphamide (FAC) as adjuvant therapy for node-positive breast cancer. Clin Breast Cancer 2002, 3:103-105.
58. Lee S.G., Jee Y.G., Chung H.C., Kim S.B., Ro J., Im Y.H., et al. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat 2009, 114:589-595.
59. Mittmann N., Verma S., Koo M., Alloul K., Trudeau M. Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer. Curr Oncol 2010, 17:7-16.
60. Boér K., Láng I., Juhos E., Pintér T., Szántó J. Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC). Pathol Oncol Res 2003, 9:166-169.
61. Martín M., Lluch A., Seguí M.A., Ruiz A., Ramos M., Adrover E., et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006, 17:1205-1212.
62. Dang C., Fornier M., Sugarman S., Troso-Sandoval T., Lake D., D'Andrea G., et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol 2008, 26:1216-1222.
63. Torrisi R., Orlando L., Ghisini R., Veronesi P., Intra M., Rocca A., et al. A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer. Anticancer Res 2006, 26:3861-3864.
64. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439.
65. Pusztai L., Mendoza T.R., Reuben J.M., Martinez M.M., Willey J.S., Lara J., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25:94-102.
66. Kannarkat G., Lasher E.E., Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol 2007, 20:719-725.
67. MacLeod J.E., DeLeo J.A., Hickey W.F., Ahles T.A., Saykin A.J., Bucci D.J. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 2007, 181:168-172.
68. Janelsins M.C., Mustian K.M., Palesh O.G., Mohile S.G., Peppone L.J., Sprod L.K., et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer 2011, 1-9.
69. Shih V., Wan H.S., Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 2009, 43:444-452.
70. Montgomery G.H., Bovbjerg D.H. Expectations of chemotherapy-related nausea: emotional and experiential predictors. Ann Behav Med 2003, 25:48-54.
71. Molassiotis A., Yam B.M.C., Yung H., Chan F.Y.S., Mok T.S.K. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 2002, 10:139-145.
72. Moon S., Kim S.H., Kim M.J. Perceived cognitive function and related factors in Korean women with breast cancer. Asian Nurs Res 2011, 5:141-150.
73. Juergens A., Pels H., Rogowski S., Fliessbach K., Glasmacher A., Engert A., et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010, 67:182-189.
74. Skaali T., Fosså S.D., Andersson S., Cvancarova M., Langberg C.W., Lehne G., et al. A prospective study of neuropsychological functioning in testicular cancer patients. Ann Oncol 2011, 22:1062-1070.
75. Wefel J.S., Vidrine D.J., Veramonti T.L., Meyers C.A., Marani S.K., Hoekstra H.J., et al. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 2011, 117:190-196.
76. Phillips K.A., Aldridge J., Ribi K., Sun Z., Thompson A., Harvey V., et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2011, 126:221-226.
77. Lethaby A., Hogervorst E., Richards M., Yesufu A., Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev 2008.
78. Loiselle C., Rockhill J. Radiation, chemotherapy, and symptom management in cancer related cognitive dysfunction. Curr Pain Headache Rep 2009, 13:271-276.
79. Kautio A.L., Haanpää M., Kautiainen H., Kalso E., Saarto T. Burden of chemotherapy-induced neuropathy-a cross-sectional study. Support Care Cancer 2010, 1-6.
80. Ferguson T., Wilcken N., Vagg R., Ghersi D., Nowak A. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007.